LOBBYIST

Matthew Flynn

Registrant in 2026 disclosures: Steptoe LLP

Based on 27 cached source filings; newest posted Oct 27, 2026. Disclosure history is not real-time employment verification.

← Back to lobbyists

Following Matthew Flynn’s registrations? Leave your email and we’ll follow up personally when their filings change.

31ACTIVITIES
16DISCLOSED CLIENTS
0BILLS

Revolving door — covered positions

Prior government positions reported in lobbying disclosures. These are historical roles, not a statement of current employment.

Mbr-HSAC

+ 5 more disclosed positions in the full intelligence view

Disclosed clients

16

Clients named in filings listing Matthew, across all filing years. Activity counts are disclosure mentions, not a list of current engagements.

Orexo US, Inc.6 activities
American Express Global Business Travel3 activities

+ 14 more disclosed clients — available with full intelligence access

Limited preview · paid research

See the research behind a profile.

Connect disclosed clients, bills and source filings. The full federal calendar and records stay paid.

Separate example—not a dossier about this person, an endorsement or proof of participation.

Federal Intelligence: $2,500 one-time for three months or $9,000 for twelve months prepaid. One named user; no automatic renewal.

Secure setup within one business day after verified payment. Your term starts at activation.

Only need a finished deliverable? Commission a focused federal research brief · $1,000 one-time →. Scope agreed before payment; no account access included.

Account options and coverage

Unlock the full client and employer history, complete bill and issue activity, professional contact sources where available, and the joined map of where this lobbyist appears across the Pulse database. Missing contacts are not presented as verified.

A free alert subscription does not grant full access.

Topics in Filings

10

Policy topics Matthew files on across all their LD-2 activities.

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding×6

+ 9 more topics in the full dossier

Pulled from the org’s own LD-2 disclosures. See the source filings ↓

Source filing samples

Most recent available disclosure for each client shown above. Consult the original filing to verify context; these samples are not the complete filing history.

Orexo US, Inc. · 2026 third_quarter filing ↗

American Express Global Business Travel · 2026 third_quarter filing ↗

Issue mix

LDA general-issue codes weighted by activity count.

Government Issues6
Manufacturing6
Budget/Appropriations4

+ 9 more issue areas in the full intelligence view

Is this you? Claim or correct this profile.